NCT04157517: A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study

NCT04157517
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase)
Exclusions: 
https://ClinicalTrials.gov/show/NCT04157517

Comments are closed.

Up ↑